scholarly journals Thromboxane A2 is a key regulator of pathogenesis during Trypanosoma cruzi infection

2007 ◽  
Vol 204 (4) ◽  
pp. 929-940 ◽  
Author(s):  
Anthony W. Ashton ◽  
Shankar Mukherjee ◽  
FNU Nagajyothi ◽  
Huan Huang ◽  
Vicki L. Braunstein ◽  
...  

Chagas' disease is caused by infection with the parasite Trypanosoma cruzi. We report that infected, but not uninfected, human endothelial cells (ECs) released thromboxane A2 (TXA2). Physical chromatography and liquid chromatography-tandem mass spectrometry revealed that TXA2 is the predominant eicosanoid present in all life stages of T. cruzi. Parasite-derived TXA2 accounts for up to 90% of the circulating levels of TXA2 in infected wild-type mice, and perturbs host physiology. Mice in which the gene for the TXA2 receptor (TP) has been deleted, exhibited higher mortality and more severe cardiac pathology and parasitism (fourfold) than WT mice after infection. Conversely, deletion of the TXA2 synthase gene had no effect on survival or disease severity. TP expression on somatic cells, but not cells involved in either acquired or innate immunity, was the primary determinant of disease progression. The higher intracellular parasitism observed in TP-null ECs was ablated upon restoration of TP expression. We conclude that the host response to parasite-derived TXA2 in T. cruzi infection is possibly an important determinant of mortality and parasitism. A deeper understanding of the role of TXA2 may result in novel therapeutic targets for a disease with limited treatment options.

2010 ◽  
Vol 220 (1-2) ◽  
pp. 64-68 ◽  
Author(s):  
Milene A. Rachid ◽  
Antônio L. Teixeira ◽  
Lucíola S. Barcelos ◽  
Conceição R.S. Machado ◽  
Egler Chiari ◽  
...  

2020 ◽  
Vol 119 (6) ◽  
pp. 1845-1845
Author(s):  
Paul Zaki ◽  
Elisa L. B. C. Domingues ◽  
Farhad M. Amjad ◽  
Maiara B. Narde ◽  
Karolina R. Gonçalves ◽  
...  

Cytokine ◽  
2018 ◽  
Vol 111 ◽  
pp. 88-96 ◽  
Author(s):  
Rafaela Pravato Colato ◽  
Vânia Brazão ◽  
Gabriel Tavares do Vale ◽  
Fabricia Helena Santello ◽  
Pedro Alexandre Sampaio ◽  
...  

2010 ◽  
Vol 12 (8-9) ◽  
pp. 669-676 ◽  
Author(s):  
Ester Roffê ◽  
Fabiano Oliveira ◽  
Adriano L.S. Souza ◽  
Vanessa Pinho ◽  
Danielle G. Souza ◽  
...  

1998 ◽  
Vol 47 ◽  
pp. 249
Author(s):  
K Hiyama ◽  
S Hamano ◽  
T Nakamura ◽  
H Takimoto ◽  
K Nomoto ◽  
...  

1984 ◽  
Vol 73 (2) ◽  
pp. 470-476 ◽  
Author(s):  
R G Lalonde ◽  
B E Holbein

1992 ◽  
Vol 263 (4) ◽  
pp. H1045-H1053
Author(s):  
S. E. Martin ◽  
J. T. Kuvin ◽  
S. Offenbacher ◽  
B. M. Odle ◽  
R. E. Patterson

We previously reported that coronary constriction following neuropeptide Y (NPY) was alleviated by cyclooxygenase blockade. To determine the role of thromboxane A2 (TxA2), anesthetized dogs received two paired doses of NPY given 2 h apart. Nine control dogs received NPY alone. Nine test dogs received one of three TxA2 receptor antagonists given between the doses of NPY. Also, five dogs received NPY during which prostaglandins were measured. In controls, NPY decreased coronary blood flow and increased aortic pressure; coronary resistance was increased significantly. Heart rate fell, and myocardial oxygen consumption was unchanged. Thromboxane receptor blockers significantly relieved the coronary constrictor effect of NPY. The reduction in coronary blood flow was blunted, while heart rate, first derivative of left ventricular pressure, and myocardial oxygen consumption were unchanged. Alleviation by TxA2 receptor blockade paralleled that reported for cyclooxygenase inhibitors. Also, significant increases in coronary venous TxA2 were seen at the time of maximal increases in coronary resistance, while prostacyclin was unchanged. In summary, TxA2 appears to mediate part of the coronary constrictor effect of NPY.


Sign in / Sign up

Export Citation Format

Share Document